Preclinical models in ovarian, breast, and lung cancer have shown that PARP inhibition can increase tumor mutational burden, enhance antigen presentation, and upregulate PD-L1 expression, collectively creating a more inflamed tumor microenvironment [21,25-30]. The gene discussed is PARP1; the disease is neoplasm.